Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

ClinicalTrials.gov ID: NCT02887859

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02887859. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Use as a Vascular Prosthesis for Femoro-Popliteal Bypass in Patients With Peripheral Arterial Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD). This study will also evaluate how safe it is to use the HAV in this manner.

Study identification

NCT ID: NCT02887859
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Humacyte, Inc.; Industry
Enrollment: 15 participants

Conditions and interventions

Conditions

Peripheral Artery Disease

Interventions

Human Acellular Vessel (HAV) Biological

Biological

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 20, 2016 (Actual)
Primary completion: Dec 2020 (Actual)
Completion: Dec 2023 (Actual)
Last update posted: Apr 18, 2025

2016 – 2023

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
UCSF	San Francisco	California	94143	—
Brigham and Women's Hospital	Boston	Massachusetts	02115	—
Michigan Vascular Center	Flint	Michigan	48507	—
Overlook Medical Center	Summit	New Jersey	07901	—
Duke University	Durham	North Carolina	27708	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02887859, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 18, 2025 · Synced Nov 15, 2026